 |
 |
|
|
Rozerem Without PrescriptionRozerem Breaf Information
Rozerem Buying Information
Buy Rozerem without prescription online What is Rozerem?
Rozerem is specifically indicated for the treatment of chronic or transient insomnia characterized by difficulty in falling asleep. Rozerem can be prescribed for long-term use - the FDA approval allows physicians to prescribe Rozerem for long-term use in adults. Rozerem has not been studied in children or adolescents, and the effects in these populations are unknown. Rozerem showed no evidence of potential abuse, dependence, or withdrawal in clinical studies. Rozerem targets the normal sleep-wake cycle. Sleep is regulated by the internal master clock in the suprachiasmatic nucleus, or the SCN. Because Rozerem works by selectively binding to receptors in the SCN, it doesn’t act by general central nervous system depression, which may explain the absence of abuse potential. Advantages:
Disadvantages:
How does Rozerem works? Rozerem is a melatonin MT1 and MT2 receptor agonist. Rozerem has a unique therapeutic mechanism of action that selectively targets two receptors located in the brain's suprachiasmatic nucleus (SCN). The SCN is known as the body's "master clock" because it regulates 24-hour, or circadian, rhythms including the sleep-wake cycle. By binding selectively at these receptors, the drug mimics and enhances the action of endogenous melatonin, which has been associated with maintenance of circadian sleep rhythm through the inhibitory activity of MT1 and MT2 systems on excitatory wakefulness-promoting circuits in the suprachiasmic nucleus. The drug showed no measurable affinity for a number of other systems, including benzodiazepine receptors, dopamine receptors, opiate receptors, ion channels, and transporters, and no effect on the activity of various enzymes. Rozerem for Chronic Insomnia Rozerem is effective in adults with chronic insomnia. Rozerem was investigated in a pair of randomized, double-blind trials designed to determine the efficacy of the drug for the treatment of chronic insomnia via polysomnography (PSG). This first study enrolled adults ages 18-64, who received one of two doses of the drug (8 mg or 16 mg) or placebo nightly before bed for 35 days. Sleep analysis via PSG was performed on days 1, 2 of weeks 1, 3 and 5. The second study enrolled elderly patients age 65 and older in a three-period crossover trial. Subjects received one of two doses of the drug (4 mg or 8 mg) or placebo in each study period, with PSG analysis performed for 2 consecutive nights in each period. In both studies, each dose of Rozerem produced significant reductions in average latency to persistent sleep onset, compared to placebo. Rozerem for Transient Insomnia Rozerem is effective in adults with transient insomnia. A randomized, double-blind, parallel-group trial was conducted to investigate the single-dose efficacy of the drug in treating transient insomnia. The trial enrolled healthy adults, who received a single dose of the drug at one of two levels (8 mg or 16 mg) or placebo before a single night of PSG analysis. The 8 mg dose was seen to significantly reduce mean latency to persistent sleep, vs. placebo. Rozerem and Next-Day Fatigue Randomized, double-blind, parallel-group trial has been shown that Rozerem does not cause significant deficits of alertness, short term learning and memory performance, and ability to concentrate on the day following treatment. Withdrawal and Rebound Insomnia In clinical studies Rozerem has shown no potential for withdrawal effects and rebound insomnia following abrupt treatment termination. Abuse Potential Unlike many other hypnotic agents, clinical and animal trials of Rozerem did not yield evidence of formation of physical dependence or abuse potential, and the drug is not a controlled substance. Side effects The most common adverse events with Rozerem are:
Rozerem dose The standard dose is 8 mg within 30 minutes of going to bed and there is no difference in adult and elderly dose recommendations. Interesting Rozerem facts
|
